Share-split context: A reverse split was recorded on Sep 2, 2025 with coefficient 0.25. A reverse split combines multiple old shares into fewer new shares and mechanically raises the quoted price per share. That mechanical increase does not restore lost investment value. The returns in this report are already split-adjusted, while reverse-split history remains a separate structural warning.

What this ETF is trying to do

The GLOBAL X GENOMICS & BIOTECHNOLOGY ETF (ticker: GNOM) is designed to invest in the genomics and biotechnology sectors. This means the fund focuses on companies involved in advanced biological research and medical technologies. As of October 7, 2026, the current price of GNOM is $66.85.

What the numbers show

The performance data for GNOM shows significant growth over recent periods, though long-term history is more mixed.

Price Return vs. Total Return

It is important to distinguish between price return (the change in the share price) and total return (which includes distributions).

• Year-to-Date (YTD): The price return is approximately 47.06%, while the total return is approximately 47.21%.

• One-Year: The price return is approximately 63.80%, while the total return is approximately 66.10%.

• Three-Year: The price return is approximately 68.30%, while the total return is approximately 70.83%.

• Five-Year: The five-year total return is approximately -22.09%.

Share Split History

GNOM has a history of a reverse split. On September 2, 2025, a reverse split occurred with a coefficient of 0.25. In a reverse split, multiple old shares are combined into fewer new shares. This causes the quoted per-share price to rise mechanically, but it does not increase the actual value of the investment. Because of this split history, an estimated price from one year ago is not provided.

Income and distribution explanation

GNOM provides some level of cash distributions, but they are not frequent. The trailing distributions are $0.6491, resulting in a distribution yield of approximately 0.97%. The payout frequency is described as "irregular" or "less frequent," with only 2 payouts recorded in the last 12 months.

While some investors look for income, a distribution yield is not the same as total return. Total return tells you the full picture of how much the investment grew, including both price changes and cash paid out.

NAV erosion explanation

"NAV erosion" refers to a decline in the Net Asset Value (the actual value of the assets held by the fund). The supplied data is sufficient to evaluate price erosion, but it does not include enough historical NAV-per-share data to confirm or rule out NAV erosion.

However, regarding price-based evidence, the fund has an erosion score of 100, which is labeled as "No price erosion detected." The erosion severity is rated as "good," and there is no severe erosion-risk flag.

Top Holdings

The following are the top holdings in the GNOM portfolio (note that this list is partial):

• MODERNA INC (7.50%)

• TWIST BIOSCIENCE CORP (6.34%)

• 10X GENOMICS INC (5.48%)

• GUARDANT HEALTH INC (5.28%)

• ILLUMINA INC (4.86%)

• NATERA INC (4.60%)

• GENSCRIPT BIOTECH CORP CLASS H (3.81%)

• VERTEX PHARMACEUTICALS INC (3.70%)

• BIO-TECHNE CORP (3.67%)

• BIOMARIN PHARMACEUTICAL INC (3.58%)

Holdings can change over time.

Pros

• Strong recent performance in both price return and total return over the one-year and three-year periods.

• No detected price erosion according to the current erosion score.

Cons

• The five-year total return is negative.

• Distributions are irregular and less frequent.

Beginner takeaway

GNOM focuses on the biotechnology sector. While it has shown very strong price and total returns over the last three years, its five-year history shows a decline. Investors should remember that high price growth in the short term does not guarantee long-term results, and irregular distributions mean income may not be steady.